Publication of List of Manufacturers Suspended from Licensing for the Manufacture of Therapeutic Goods under Section 41

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, governs the regulation of therapeutic goods in the country. This legislation was introduced to ensure the safety, quality, and efficacy of therapeutic goods available in the market, thereby protecting public health. A significant problem the Act addresses is the potential risk posed by substandard or unsafe therapeutic goods, which can lead to serious health consequences. The Act empowers the Therapeutic Goods Administration (TGA) to monitor and control the manufacturing, importation, and supply of therapeutic goods. The policy objective of the Act is to safeguard the health of Australians by ensuring that therapeutic goods are of acceptable quality and pose no unacceptable risk to public health when used according to their approved indications. In line with its objectives, the Therapeutic Goods Act 1989 includes provisions for the suspension of manufacturing licenses where there are concerns about compliance with quality standards. The publication by the Delegate of the Secretary of the Department of Health, Therapeutic Goods Administration, concerning the suspension of a Licence to Manufacture Therapeutic Goods for Veolia Environmental Services (Australia) Pty Ltd, exemplifies the Act's mechanism to enforce regulatory compliance. This specific instance highlights the TGA's authority to suspend licenses, in this case at the request of the manufacturer, to address potential issues related to the manufacturing quality of therapeutic goods.

Scope and Application

The Therapeutic Goods Act 1989 applies to entities and individuals involved in the manufacture, supply, import, and distribution of therapeutic goods within Australia. This legislation encompasses a wide range of products, including medicines, medical devices, blood, and tissues, ensuring that these goods meet safety, quality, and efficacy standards. The Act applies to any person or entity conducting activities related to therapeutic goods, which include manufacturers like Veolia Environmental Services (Australia) Pty Ltd, distributors, importers, and others involved in the therapeutic goods supply chain. The jurisdictional reach of the Act is national, applying across the Commonwealth of Australia, including states and territories. The Act includes provisions for the suspension of manufacturing licences, as seen in the notice regarding Veolia Environmental Services (Australia) Pty Ltd, demonstrating the authority's ability to regulate and enforce compliance through licensing mechanisms. Any exclusions, exemptions, or specific thresholds are outlined in the various sections of the Act, with further details and specific application provided through subordinate instruments and regulations.

Key Provisions

The Therapeutic Goods Act 1989 (the "Act") contains various sections that govern the regulation of therapeutic goods in Australia. Among these, Section 41(1)(d) is particularly significant as it allows for the suspension of a licence to manufacture therapeutic goods under certain conditions. In this instance, the Therapeutic Goods Administration, represented by Hongxia Jin, has exercised this power. This particular notice (C2017G01030) pertains to the suspension of the licence held by Veolia Environmental Services (Australia) Pty Ltd (Licence No. MI-28072005-LI-000720-1). The notice specifies that this suspension is effective from 7 August 2017 to 4 July 2018, and it was carried out at the request of the manufacturer itself. Under this Act, the obligations imposed on the parties involved, particularly the licensee, are quite stringent. The manufacturer must ensure compliance with all regulatory standards and quality controls required by the Therapeutic Goods Administration. They must also maintain accurate and comprehensive records of their manufacturing processes and product distribution. Failure to adhere to these obligations can lead to severe repercussions, including the suspension or revocation of their licence. The Act also delineates specific offences and penalties for non-compliance. Any breach of the Act's provisions could result in both civil and criminal consequences. For instance, knowingly manufacturing or supplying therapeutic goods that do not meet the required standards could be considered an offence under Section 12 of the Act. The maximum penalty for such an offence can include fines of up to $330,000 for a corporation and imprisonment for up to three years. Additionally, Section 15 of the Act provides for civil penalties, including fines of up to $1,650,000 for corporations, which further underscores the seriousness with which the Act treats non-compliance. These stringent measures are designed to ensure the safety and efficacy of therapeutic goods available in the Australian market.